Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Arthritis Care Res (Hoboken) ; 72(5): 692-698, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-30980467

RESUMO

OBJECTIVE: The present study was undertaken to investigate whether Latina and African American women with arthritis-related knee pain and primary care providers who treat them believe their treatment decisions would benefit from having more information about the impact of treatment on their quality of life, medical care costs, and work productivity. METHODS: We conducted 4 focus groups of Latina and African American women over age 45 years who had knee pain. We also conducted 2 focus groups with primary care providers who treated Latina and African American women for knee pain. The participants were recruited from the community. They were asked their opinions about a decision tool that presented information on a range of treatment options and their impacts on quality of life, medical care costs, and work productivity. They were asked whether providing this information would help them make better treatment decisions. We analyzed the focus group transcripts using ATLAS.ti. RESULTS: We found that minority women and primary care providers endorsed the use of a decision-making tool that provided information of the impact of treatment on quality of life, medical care costs, and work productivity. Providers felt that patients would benefit from having the additional information but were concerned about its complexity and some patients' ability to comprehend the information. CONCLUSION: Latina and African American women could make more informed treatment decisions for their knee pain using a decision-making tool that provides them with significant information about how various treatment options may impact their quality of life, medical care costs, and workforce productivity.


Assuntos
Artralgia/economia , Artralgia/terapia , Negro ou Afro-Americano/psicologia , Tomada de Decisão Clínica , Custos de Cuidados de Saúde , Conhecimentos, Atitudes e Prática em Saúde/etnologia , Hispânico ou Latino/psicologia , Osteoartrite do Joelho/economia , Osteoartrite do Joelho/terapia , Médicos de Atenção Primária/psicologia , Qualidade de Vida , Artralgia/etnologia , Artralgia/psicologia , Atitude do Pessoal de Saúde , Comportamento de Escolha , Análise Custo-Benefício , Assistência à Saúde Culturalmente Competente/etnologia , Técnicas de Apoio para a Decisão , Emprego , Feminino , Grupos Focais , Humanos , Pessoa de Meia-Idade , Osteoartrite do Joelho/etnologia , Osteoartrite do Joelho/psicologia , Seleção de Pacientes , Atenção Primária à Saúde , Fatores Raciais , Recuperação de Função Fisiológica , Resultado do Tratamento
2.
Med Care ; 55(12): 993-1000, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-29036012

RESUMO

BACKGROUND: Disparities in the presentation of knee osteoarthritis (OA) and in the utilization of treatment across sex, racial, and ethnic groups in the United States are well documented. OBJECTIVES: We used a Markov model to calculate lifetime costs of knee OA treatment. We then used the model results to compute costs of disparities in treatment by race, ethnicity, sex, and socioeconomic status. RESEARCH DESIGN: We used the literature to construct a Markov Model of knee OA and publicly available data to create the model parameters and patient populations of interest. An expert panel of physicians, who treated a large number of patients with knee OA, constructed treatment pathways. Direct costs were based on the literature and indirect costs were derived from the Medical Expenditure Panel Survey. RESULTS: We found that failing to obtain effective treatment increased costs and limited benefits for all groups. Delaying treatment imposed a greater cost across all groups and decreased benefits. Lost income because of lower labor market productivity comprised a substantial proportion of the lifetime costs of knee OA. Population simulations demonstrated that as the diversity of the US population increases, the societal costs of racial and ethnic disparities in treatment utilization for knee OA will increase. CONCLUSIONS: Our results show that disparities in treatment of knee OA are costly. All stakeholders involved in treatment decisions for knee OA patients should consider costs associated with delaying and forgoing treatment, especially for disadvantaged populations. Such decisions may lead to higher costs and worse health outcomes.


Assuntos
Artroplastia do Joelho/economia , Disparidades em Assistência à Saúde/economia , Modelos Econômicos , Osteoartrite do Joelho/economia , Artroplastia do Joelho/estatística & dados numéricos , Análise Custo-Benefício , Feminino , Custos de Cuidados de Saúde , Necessidades e Demandas de Serviços de Saúde/economia , Disparidades nos Níveis de Saúde , Humanos , Masculino , Osteoartrite do Joelho/epidemiologia , Estados Unidos
3.
Am J Manag Care ; 22(6 Spec No.): SP191-7, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-27266948

RESUMO

OBJECTIVES: To describe rates of sofosbuvir initial medication adherence as a function of the insurer-required member cost (ie, out-of-pocket cost) and to determine how manufacturer coupons affect insurer-required member cost. STUDY DESIGN: Observational cross-sectional analysis. METHODS: Administrative pharmacy claims data from 13 million commercially insured members were used to identify sofosbuvir new starts between January 2014 and September 2014. Members were categorized as either sofosbuvir initial adherence or as abandoning therapy. A multivariate logistic regression model adjusting for sociodemographic characteristics, severity of illness, and total drug costs (health insurer plus member amount) for non-sofosbuvir pharmacy claims in 2014 was used to evaluate the association between insurer-required member cost and initial medication adherence. In a sub-analysis, sofosbuvir index claims with coupon data available were analyzed to determine how coupon use impacted insurer-required member cost. RESULTS: A total of 67.3% of members had a pre-coupon member cost of < $250 for their index sofosbuvir claim. Just 201 (5.0%) members were exposed to a member cost of more than $10,000. The logistic regression model demonstrated an association between member cost and abandonment starting at $2500 to < $5000 (odds ratio: 1.9; 95% CI, 1.01-3.43; P = .0393). The average member sofosbuvir index claim cost was $1349 before coupon was applied, and $28 after. Overall, coupons offset the member amounts paid by 98%: $771,593 of the $787,860 member cost requested by the insurer. CONCLUSIONS: These findings indicate that a 30-day supply sofosbuvir member cost of > $2500 was associated with increased initial therapy abandonment, and that manufacturer coupons substantially reduced sofosbuvir insurer-required member cost. Insurers and policy makers should consider the impact of member cost on medication adherence and the impact coupons have on the actual member cost.


Assuntos
Custo Compartilhado de Seguro/economia , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/economia , Seguro de Serviços Farmacêuticos/economia , Adesão à Medicação/estatística & dados numéricos , Sofosbuvir/economia , Antivirais/economia , Antivirais/uso terapêutico , Custo Compartilhado de Seguro/métodos , Custo Compartilhado de Seguro/estatística & dados numéricos , Análise Custo-Benefício , Estudos Transversais , Hepatite C Crônica/complicações , Humanos , Revisão da Utilização de Seguros , Modelos Logísticos , Análise Multivariada , Honorários por Prescrição de Medicamentos/estatística & dados numéricos , Sofosbuvir/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...